Category: breast

Good News for Breast Cancer Patients with HER2-positive

Good News for Breast Cancer Patients with HER2-positive

The first paragraph summed it well - drastic price reduction would enable more breast cancer patients with HER2-positive to be treated with trastuzumab. Trastuzumab treatment is heavily subsidised for patients who fits certain criteria in government hospitals. For these patients, this news won't affect them. Who will it benefit then? Besides adhering to KKM drug … Continue reading Good News for Breast Cancer Patients with HER2-positive

Early Breast Cancer: Importance of Hormonal Therapy in ER-positive Breast Cancer

Early Breast Cancer: Importance of Hormonal Therapy in ER-positive Breast Cancer

A young lady in her early 40s had left breast cancer, pT2N2MO (stage III), ER positive, HER2 negative. She completed surgery, chemotherapy and radiotherapy. When I told her that she will need hormonal therapy for up to 10 years based on latest study, she said the study must be pharma-sponsored to encourage longer use of … Continue reading Early Breast Cancer: Importance of Hormonal Therapy in ER-positive Breast Cancer

Living Longer: Advanced Breast Cancer (ABC) – HER2 over-expressed (2nd line treatments)

Living Longer: Advanced Breast Cancer (ABC) – HER2 over-expressed (2nd line treatments)

What Happen When First-Line Treatment Fails? In advanced or metastatic breast cancer, first-line treatment will fail after certain duration of time. This is because cancer cells developed resistance to the treatment and not because the treatment is ineffective. Life doesn't end when first-line treatment fails. We just continue fighting the cancer with other effective second-line … Continue reading Living Longer: Advanced Breast Cancer (ABC) – HER2 over-expressed (2nd line treatments)

Living Longer: Advanced Breast Cancer (ABC) – HER2 over-expressed (1st line treatments)

Living Longer: Advanced Breast Cancer (ABC) – HER2 over-expressed (1st line treatments)

Introduction HER2 over-expression constitutes around 20% of all breast cancer. Two different methods are being used to test for HER2 over-expression, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) Immunohistochemistry (IHC); identifies HER2 expression on the cell surface, with a grading system of 0 to 3+ positive. tumors are classed as HER2-positive if they have … Continue reading Living Longer: Advanced Breast Cancer (ABC) – HER2 over-expressed (1st line treatments)

Living Longer: Advanced Breast Cancer (ABC) – Triple Negatives; ER/PR/HER2 (-ve)

Living Longer: Advanced Breast Cancer (ABC) – Triple Negatives; ER/PR/HER2 (-ve)

Introduction Breast cancer is not a single disease but comprised of distinct biological subtypes with different prognosis and treatment options: Luminal A: ER/PR+ve, Her2-ve Luminal B: ER/PR+ve, Her2+ve HER2 over-expressed: Her2+ve Triple negatives/ basal-like: ER/PR-ve, Her2−ve Among the different subtypes above, triple negative breast cancer (TNBC) accounts for 10%-15% of breast cancer diagnosed. TNBC carries the worst prognosis and … Continue reading Living Longer: Advanced Breast Cancer (ABC) – Triple Negatives; ER/PR/HER2 (-ve)